Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment
E Minos, RJ Barry, S Southworth, A Folkard… - Orphanet Journal of …, 2016 - Springer
Birdshot chorioretinopathy (BCR) is a rare form of chronic, bilateral, posterior uveitis with a
distinctive clinical phenotype, and a strong association with HLA-A29. It predominantly …
distinctive clinical phenotype, and a strong association with HLA-A29. It predominantly …
Ocular immunosuppressive microenvironment and novel drug delivery for control of uveitis
S Teabagy, E Wood, E Bilsbury, S Doherty… - Advanced Drug Delivery …, 2023 - Elsevier
Ocular immune privilege is a phenomenon described by Peter Medawar in relation to the
indefinite survival of the placement of foreign tissue grafts into the eye. Several mechanisms …
indefinite survival of the placement of foreign tissue grafts into the eye. Several mechanisms …
Intravitreal dexamethasone implant as a sustained release drug delivery device for the treatment of ocular diseases: a comprehensive review of the literature
C Iovino, R Mastropasqua, M Lupidi, D Bacherini… - Pharmaceutics, 2020 - mdpi.com
Drug delivery into the vitreous chamber remains a great challenge in the pharmaceutical
industry due to the complex anatomy and physiology of the eye. Intravitreal injection is the …
industry due to the complex anatomy and physiology of the eye. Intravitreal injection is the …
Dexamethasone Intravitreal Implant (OZURDEX®) for Macular Edema Secondary to Noninfectious Uveitis: a Review of the Literature
H Massa, P Georgoudis, GD Panos - Therapeutic delivery, 2019 - Taylor & Francis
Macular edema (ME) is the leading cause of visual loss in uveitis and may persist long after
ocular inflammation has been resolved. Local steroids are the first line treatment for uveitis …
ocular inflammation has been resolved. Local steroids are the first line treatment for uveitis …
A review of ocular drug delivery platforms and drugs for infectious and noninfectious uveitis: the past, present, and future
CD Conrady, S Yeh - Pharmaceutics, 2021 - mdpi.com
Uveitis refers to a broad group of inflammatory disorders of the eye that often require
medical and surgical management to improve or stabilize vision and prevent vision …
medical and surgical management to improve or stabilize vision and prevent vision …
Real-life efficacy, safety, and use of dexamethasone intravitreal implant in posterior segment inflammation due to non-infectious uveitis (LOUVRE 2 Study)
B Bodaghi, AP Brézin, M Weber, C Delcourt… - Ophthalmology and …, 2022 - Springer
Introduction To evaluate real-life efficacy, safety, and treatment patterns with the
dexamethasone intravitreal implant (DEX) in posterior segment inflammation due to non …
dexamethasone intravitreal implant (DEX) in posterior segment inflammation due to non …
[HTML][HTML] A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or …
H Squires, E Poku, I Bermejo, K Cooper… - Health Technology …, 2017 - europepmc.org
Background Non-infectious intermediate uveitis, posterior uveitis and panuveitis are a
heterogeneous group of inflammatory eye disorders. Management includes local and …
heterogeneous group of inflammatory eye disorders. Management includes local and …
Ozurdex (dexamethasone intravitreal implant) for the treatment of intermediate, posterior, and panuveitis: a systematic review of the current evidence
SS Saincher, C Gottlieb - Journal of Ophthalmic Inflammation and Infection, 2020 - Springer
Background This study aims to determine if the intravitreal dexamethasone implant (DEX
implant, Ozurdex; Allergan, Inc., Irvine, California) is effective for treating intermediate …
implant, Ozurdex; Allergan, Inc., Irvine, California) is effective for treating intermediate …
Ocular involvement in sarcoidosis
F Groen, A Rothova - … in Respiratory and Critical Care Medicine, 2017 - thieme-connect.com
Ocular involvement in sarcoidosis occurs in∼ 40% and the eye is the presenting organ in
roughly 20%. The course of ocular disease does not necessarily parallel that of systemic …
roughly 20%. The course of ocular disease does not necessarily parallel that of systemic …
Prospective evaluation of a sustained-release dexamethasone intravitreal implant for cystoid macular edema in quiescent uveitis
RN Khurana, AS Bansal, LK Chang, JD Palmer, C Wu… - Retina, 2017 - journals.lww.com
Purpose: To investigate dexamethasone intravitreal implant (DEX implant; OZURDEX,
Allergan, Inc) in the treatment of uveitic cystoid macular edema that had persisted in the …
Allergan, Inc) in the treatment of uveitic cystoid macular edema that had persisted in the …